TD Cowen Maintains Buy on Krystal Biotech, Raises Price Target to $403
HC Wainwright & Co. Maintains Buy on Krystal Biotech, Raises Price Target to $361
Is the Options Market Predicting a Spike in Krystal Biotech Stock?
Krystal Biotech Stock Soars 16% in Three Months: Here's Why
Why Is Krystal Biotech (KRYS) Up 3% Since Last Earnings Report?
HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $310 Price Target
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech Says UK MHRA Grants Marketing Authorization To VYJUVEK For Treatment Of Wounds In Patients With Dystrophic Epidermolysis Bullosa With Mutation(s) In COL7A1 Gene, From Birth
MHRA Approves Beremagene Geperpavec For The Treatment Of Dystrophic Epidermolysis Bullosa
Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Krystal Biotech: Vyjuvek Is Not The Primary Asset
Krystal Biotech (NASDAQ:KRYS) Combines Perfect Trend Template with High-Growth Momentum
Krystal Biotech, Inc. 2026 Q1 - Results - Earnings Call Presentation
Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027
Krystal Biotech Analysts Boost Their Forecasts Following Upbeat Q1 Results
Citigroup Maintains Buy on Krystal Biotech, Raises Price Target to $378
Evercore ISI Group Maintains Outperform on Krystal Biotech, Raises Price Target to $300
Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call Transcript
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.
